SVCM
MLTX icon

Saturn V Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Saturn V Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-290,784
Closed -$13.7M – 21
2025
Q2 		$13.7M Sell
290,784
-53,065
-15% -$2.16M 5.56% 10
2025
Q1 		$13.4M Sell
343,849
-2,262
-0.7% -$97.5K 6.78% 6
2024
Q4 		$18.7M Buy
346,111
+47,137
+16% +$2.41M 7.34% 3
2024
Q3 		$15.1M Buy
+298,974
New +$14M 5.39% 9

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Saturn V Capital Management's MLTX Position: Q3 2025 in Review

Saturn V Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 290,784 shares — an estimated $13.7M sold.

Saturn V Capital Management first reported a position in MLTX in Q3 2024 and held it in 4 quarters. The position peaked at $18.7M in Q4 2024. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Saturn V Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Saturn V Capital Management sold 290,784 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $13.7M.
  • Saturn V Capital Management first reported a position in MoonLake Immunotherapeutics in Q3 2024 and held it in 4 quarters.
  • Saturn V Capital Management's MoonLake Immunotherapeutics position peaked at $18.7M in Q4 2024.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Saturn V Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.